[The polypill: optimal strategy for reduction of cardiovascular disease].
Treating all persons above 55 years of age with a polypill for primary and secondary cardiovascular-disease prevention may reduce cardiovascular events by more than 80%. This strategy is expected to be cost-effective and the associated risk of side effects is estimated to be low.
Nathoe
H M
HM
Universitair Medisch Centrum Utrecht, afd. Cardiologie, Postbus 85.500, 3508 GA Utrecht.
Doevendans
P A F M
PA
D000959:Antihypertensive Agents / Q000008:administration & dosage*; D001241:Aspirin / Q000008:administration & dosage*; D002318:Cardiovascular Diseases / Q000401:mortality / Q000517:prevention & control*; D003362:Cost-Benefit Analysis; D004338:Drug Combinations; D005260:Female; D005492:Folic Acid / Q000008:administration & dosage*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage*; D011322:Primary Prevention
D000959:Antihypertensive Agents; D004338:Drug Combinations; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D010975:Platelet Aggregation Inhibitors; D005492:Folic Acid; D001241:Aspirin